How many insider trades does FilingIQ track for MGX?

FilingIQ tracks 55 Form 4 insider transactions for MGX (Metagenomi Therapeutics, Inc.), covering filings from Feb 9, 2024 onwards. 9 of those were filed in the last 90 days.

Are MGX insiders net buyers or net sellers?

Across the full Form 4 history for MGX, 2 transactions (4%) were open-market purchases and 20 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MGX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MGX in?

Metagenomi Therapeutics, Inc. (MGX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $60.07M.

MGX insider trading

NasdaqGS Healthcare

Metagenomi Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

4% / 36%

Market cap

$60.07M

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in EmeryVille, California.

Company website: metagenomi.co

MGX insider activity at a glance

FilingIQ has scored 55 insider transactions for MGX since Feb 9, 2024. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 2 open-market purchases and 20 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MGX insider trades is 60.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MGX trades on FilingIQ Raw filings on SEC EDGAR

Latest MGX Form 4 filings

Wapnick Pamela Chief Financial Officer

S Sep 5, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MGX?: FilingIQ tracks 55 Form 4 insider transactions for MGX (Metagenomi Therapeutics, Inc.), covering filings from Feb 9, 2024 onwards. 9 of those were filed in the last 90 days.
Are MGX insiders net buyers or net sellers?: Across the full Form 4 history for MGX, 2 transactions (4%) were open-market purchases and 20 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MGX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MGX in?: Metagenomi Therapeutics, Inc. (MGX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $60.07M.

Methodology & sources

Every MGX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.